Journals / Van Tıp Dergisi / 2005 / Cilt: 12 - Sayı: 2

L-asparaginase related toxicity in childhood acute lymphoblastic leukemia

Çocukluk çağı akut lenfoblastik lösemi olgularında L-asparajinaz'a bağlı toksisite

Pages
149–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

L-asparaginase toxicity rate of our patients are similar compared to the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although L-asparaginase has a high rateoftoxicity, it is a component of childhood acute lymphoblastic leukemia (ALL) therapy with vincristine and prednisolone and it increases cure rate, In. this article, we analysed adverse effects of L- asparaginase treatments in 85 ALL patients respectively.
📊
Key Findings & Data:Adverse reactions were observed, in 28 (32,9%) patients.
💡
Conclusion & Impact:L-asparaginase toxicity rate of our patients are similar compared to the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç toksisitesi · Lösemi · lenfositik

Abstract

Although L-asparaginase has a high rateoftoxicity, it is a component of childhood acute lymphoblastic leukemia (ALL) therapy with vincristine and prednisolone and it increases cure rate, In. this article, we analysed adverse effects of L- asparaginase treatments in 85 ALL patients respectively. Adverse reactions were observed, in 28 (32,9%) patients. Allergy, hyperglycemia and hypertrigliseridemia were the most common adverse reactions in our patients. Less common adverse reactions were pancreatitis, parotiditis and thrombosis. In conclusion. L-asparaginase toxicity rate of our patients are similar compared to the literature.

Özet

L-Asparajinaz yüksek oranda toksisiteye sahip olmakla birlikte çocukluk çağı akut lenfoblastik lösemi (ALL) tedavisinde vinkristin ve prednizon ile başlama tedavisinin standart bileşenidir ve başarıyı önemli oranda artırır. Bu çalışmada indüksiyon kemoterapisinde L-asparaginaz kullandığımız 85 ALL'Ii olguda gelişen yan etkiler ye tedavileri incelendi. Olgularımızın 28 (%32.9) tanesinde L-aşparaginaza bağlı yan etki gelişti. Olgularımızda en sık görülen yan etkiler allerji, hiperglisemi ve hipertrigliseridemi idi. Daha az görülen yan etkiler ise pankreatit, parotitis ve trombozdu. Sonuç olarak, olgularımızdaki L-asparaginaza bağlı toksisite görülme sıklığı ve tipi ülkemizde diğer merkezlerden bildirilen oranlara benzer olarak izlendi.

🔖

Cite This Article

BAY, A., ÖNER, A. F., CESUR, Y., DEMİR, C., MUKUL, Y., AÇIKGÖZ, M. (2005). L-asparaginase related toxicity in childhood acute lymphoblastic leukemia. Van Tıp Dergisi, Cilt: 12 - Sayı: 2, 149–152. https://ajindex.com/articles/334627

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Panosyan EH, Grigoryan RS, Avramis IA, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 24: 1121- 5, 2004
  2. Holcenberg J. Optimal asparaginase therapy. J Pediatr Hematol Oncol 26: 273-4, 2004
  3. Priest JR, Ramsay NKC, Bennett AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr 100: 990- 5, 1982
  4. Cetin M, Yetgin S, Kara A, et al. Hyperglycemia, ketoacidosis and other complications of Lasparaginase in children with acute lymphoblastic leukemia. J Med 25: 219- 29, 1994
  5. Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol 34: 200- 5, 2000
  6. Cremer P, Lakomek M, Beck W, Prindull G. The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukemia. Eur J Pediatr; 147: 64- 7, 1988
  7. Weiss RB. Hypersensitivity reactions. Semin Oncol 19: 458- 77, 1992
  8. Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams TE. Toxicity of L-asparginase in children with advanced leukemia. Cancer 30:339-47, 1972
  9. Clavell LA, Gelber RD, Cohen HJ et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-63, 1986
  10. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA, Avramis VI. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo 18: 107- 12, 2004
  11. Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemiaa: a Pediatric Oncology Group Study. Blood 96: 1709- 15, 2000
  12. Akarsu S, Yılmaz E, Aygün D, Gözdaşoğlu S. Akut lenfoblastik lösemili çocuklarda L-Asparajinaz tedavisi ve komplikasyonları. Türk Pediatri Arşivi 39:162-70, 2004
  13. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 16:225-43, 2002
  14. Pui CH, Burghen GA, Bow man WP, Aur RJA. Risk fac tors for hyperglycemia in chil dren with leu ke mia re ceiv ing L-asparaginase and prednisolone. J Pediatr 99:46-50, 1981
  15. Wang YJ, Chu HY, Shu SG, Chi CS. Hyperglycemia in duced by chemotherapeutic agents used in acute lymphoblastic leukemia: re